Logo of plosonePLoS OneView this ArticleSubmit to PLoSGet E-mail AlertsContact UsPublic Library of Science (PLoS)
PLoS One. 2010; 5(3): e9633.
Published online 2010 Mar 10. doi:  10.1371/journal.pone.0009633
PMCID: PMC2835762

The RGD Domain of Human Osteopontin Promotes Tumor Growth and Metastasis through Activation of Survival Pathways

Mikhail V. Blagosklonny, Editor



Human osteopontin (OPN), a known tumor associated protein, exists in different isoforms, whose function is unclear. It also possesses a RGD domain, which has been implicated in diverse function. Here, we use genetic approaches to systematically investigate the function of the RGD domain in different OPN isoforms on tumor progression and metastasis for 2 different solid tumor models.

Methodology/Principal Findings

Using isoform-specific qRT-PCR, we found that OPN-A and B were the main isoforms overexpressed in evaluated human tumors, which included 4 soft tissue sarcomas, 24 lung and 30 head and neck carcinomas. Overexpression of either OPN-A or B in two different cell types promoted local tumor growth and lung metastasis in SCID mouse xenografts. However, expression of either isoform with the RGD domain either mutated or deleted decreased tumor growth and metastasis, and resulted in increased apoptosis by TUNEL staining. In vitro, whereas mutation of the RGD domain did not affect cell-cell adhesion, soft agar growth or cell migration, it increased apoptosis under hypoxia and serum starvation. This effect could be mitigated when the RGD mutant cells were treated with condition media containing WT OPN. Mechanistically, the RGD region of OPN inhibited apoptosis by inducing NF-κB activation and FAK phosphorylation. Inhibition of NF-κB (by siRNA to the p65 subunit) or FAK activation (by a inhibitor) significantly increased apoptosis under hypoxia in WT OPN cells, but not in RGD mutant cells.


Unlike prior reports, our data suggest that the RGD domain of both OPN-A and B promote tumor growth and metastasis mainly by protecting cells against apoptosis under stressed conditions and not via migration or invasion. Future inhibitors directed against OPN should target multiple isoforms and should inhibit cell survival mechanisms that involve the RGD domain, FAK phosphorylation and NF-κB activation.


Osteopontin (OPN) is a phosphoglycoprotein that has important physiological functions in bone remodeling [1], immune response and inflammation [2], [3]. It is also a tumor-associated protein, which mediates tumor transformation and malignant progression [4], [5]. Elevated OPN levels have been shown to correlate with increased tumor progression and poor survival in many solid tumors [6]. OPN has been proposed to promote tumor progression through several mechanisms, including increased cell survival, migration, invasion, neovascularization, and modulation of immune function [7].

When OPN was first identified and sequenced from a rat osteosarcoma phage library, it was found to contain the RGD sequence that is known to be present on fibronectin and binds to integrins [8]. Therefore, it was hypothesized that the RGD domain of OPN functionally mediates cell adhesion, migration and invasion through integrin engagement. Further studies confirmed these proposed functions of the OPN RGD domain in osteoblasts, endothelial cells and certain cancer cell lines [5]. However, most of these studies employed recombinant OPN (which lacks post-translational modifications), competing synthetic RGD peptides or their mutated versions, and αvβ3 integrin blocking antibodies to investigate the role of the RGD domain [9], [10], [11], [12], [13]. Some studies used purified OPN derived from non-cancer sources such as breast milk, bones, osteoblasts or smooth muscle cells [14], [15], [16], [17]. However, recent data have shown that the pattern of OPN post-translational modification, specifically phosphorylation, is cell-type dependent and may affect the degree of cell adhesion to this molecule [4], [18], [19], [20]. For example, OPN from ras-transformed mouse fibroblasts has less phosphorylation than OPN from differentiated mouse osteoblasts and can bind more readily to MDA435, a breast cancer cell line [19]. Similarly, tumor derived OPN has been shown to exist in a secreted form, not bound to the extracellular matrix, and unable to support cell adhesion when added to the condition media [21]. Therefore, the question of whether the RGD domain of tumor-derived OPN indeed mediates cell adhesion and migration has not been directly addressed. Only one study has attempted to answer this question by overexpressing full-length OPN-B splice form and the same construct with the RGD domain deleted in one breast cancer cell line [22]. This study revealed that loss of the RGD region partially decreased lymphatic metastasis in a breast cancer model, however, deletion of the entire domain may result in unpredictable structural effects that can interfere with function.

Another layer of added complexity is that human OPN gene is subject to alternative splicing, which yields three distinct isoforms: OPN-A (full-length transcript), OPN-B (lacks exon 5 or 14 amino acids) and OPN-C (lacks exon 4 or 28 amino acids) [23]. The relative expression of the 3 isoforms in human tumors and their function is not well characterized. While one study suggested that OPN-C was selectively expressed in invasive breast cancer and more likely to support anchorage independent tumor growth than OPN-A [24], another study indicated that OPN-C was less likely to promote cell migration and invasion than the other 2 OPN isoforms in mesothelioma cells [25]. These differences in OPN isoform expression have not consistently been investigated.

To address the function of the RGD domain in tumor-derived OPN for different splice forms and in the different human tumor cell lines, we overexpressed (1) wild type OPN (WT), (2) OPN with mutations in the RGD domain (RAA), or (3) OPN with the RGD deleted (NoRGD) for the two different splice forms: OPN-A and OPN-B. We have previous analyzed several primary human cancers, including soft tissue sarcomas (STS), non-small cell lung cancers (NSCLC) and head and neck squamous cell carcinomas (HNSCC) and found that OPN-A and B but not C had elevated expression in these tumors compared to matched normal tissues. Overexpression of either the WT OPN-A or OPN-B isoform resulted in enhanced tumor growth and metastatic lung colony formation in two cell types. This effect appeared to be mediated through the RGD segment since either mutation or deletion of this domain abolished OPN-enhancement of tumor growth or metastasis. Comparison of RGD-mutated and RGD-WT tumors indicated that OPN-promotion of tumor growth was due to less apoptosis in WT cells. In vitro studies showed that RGD mutation did not affect cell adhesion, migration or invasion in these cell lines. However, it increased cell apoptosis under hypoxia and serum starvation when compared to WT OPN expressing cells, and this effect was partly restored with condition media enriched in WT OPN. OPN anti-apoptotic effect was signaled mainly through the activation of FAK and NF-κB on further investigation. Taken together, these results suggest that the RGD domain of tumor-derive OPN promotes tumor growth and metastasis mainly through cell survival mechanisms, involving FAK and NF-κB in our model.

Materials and Methods

Cell Lines & Hypoxia Treatment

MiaPaCa-2 (human pancreatic cancer cell line), HT1080 (human fibrosarcoma cell line), FaDu (human HNSCC cell line), NCI-460 (human NSCLC cell line) and MDA231 (human breast carcinoma cell line) were obtained from the American Type Culture Collection (ATCC). SCC22B (human HNSCC cell line) was obtained from the University of Michigan (Courtesy Dr. Carey). Cell lines were maintained in DMEM supplemented with 10% fetal bovine serum. For hypoxia treatments, the cells were maintained in an anoxia chamber (Sheldon Manufacturing, Cornelius, OR) with an estimated pO2<0.02% for specified durations.


The following antibodies were used: mouse monoclonal antibodies against phospho-tyrosine 397 FAK, total FAK and human Bcl-2 (BD Biosciences, San Jose, CA), mouse monoclonal anti-XIAP antibody (Abcam, Cambridge, MA), mouse monoclonal anti-β-actin antibody (Sigma-Aldrich, St Louis, MO), and rabbit polyclonal antibodies against AKT and phospho-serine 473 AKT (Cell Signaling, Danvers, MA).

Construction of OPN Plasmids and Transfection

Human OPN constructs were cloned into pcDNA 3.1 vector (Invitrogen, Carlsbad, CA). OPN-A was PCR amplified and OPN-A-RAA was generated by site-directed mutagenesis. OPN-B and OPN-B-NoRGD (RGD deleted) were gifts from Dr. Alison Allan (Univ. of Western Ontario) [22]. HT1080 and MiaPaCa-2 cells were transfected using Lipofectamine 2000 (Invitrogen).


Immunoblotting was performed as previously described [26]. Briefly, cells were lysed using 9 M urea and 75 mM Tris HCl (pH 7.5) lysis buffer supplemented with 150 mM β-mercaptoethanol. Equivalent amounts of protein were denatured, electrophoresed, and transferred to membranes. After incubation/washing with the appropriate primary and secondary antibodies, proteins were detected by Amersham ECL (GE Healthcare) and autoradiography film.

In Vitro Cell Proliferation, Adhesion, Soft Agar Growth, Migration, Scratch and NF-κB Luciferase Reporter Assays

All assays below were performed in serum free media whenever appropriate to ensure that no exogenous OPN was added. In vitro cell proliferation was assessed by cell counts with a hemacytometer. To assess in vitro cell adhesion, FaDu HNSCC cells expressing different OPN constructs were plated in 24-well plates and incubated overnight. Luciferase expressing FaDu cells were then added to each well and allowed to adhere for 30 or 60 minutes. After non-adherent cells were washed away, residual luciferase activity was measured. Cell-cell adhesion, measured by residual luciferase signal, was quantified as a percentage of the total luciferase activity from input luciferase expressing FaDu cells [27]. For the soft agar colony formation assay, MiaPaCa-2 cells (5×103), overexpressing different OPN constructs, were plated on soft agar and grown for 10-14 days followed by crystal violet staining. The number of colonies/plate and colony size, expressed as average area, were quantified using RT-Image software [28]. The scratch assay was performed with MiaPaCa-2 cells, overexpressing various constructs. Upon growth to confluency, cells were pipet scratched, cultured in serum-free media and maintained in hypoxia for 24 hours [29]. NF-κB luciferase assays were carried out as previously described [26].

Reverse Transcription Polymerase Chain Reaction Analysis (RT-PCR)

RNA purification and RT-PCR was performed as previously described [26]. The following oligomers were used for RT-PCR: forward 5′- TTGCTTTTGCCTCCTAGGCA-3′ and reverse 5′-GTGAAAACTTCGGTTGCTGG-3′.


OPN ELISAs were performed as previously described [30].

Tumor Growth and Metastasis

All animal studies were approved by the Stanford University Administrative Panel on Laboratory Animal Care (APLAC). HT1080 (2.5×106 cells/injection) or MiaPaCa-2 (2×106 cells/injection) cells expressing different OPN constructs were implanted into the flanks of SCID mice. Tumors were measured every 2–3 days. Tumor volume was calculated by the formula (π x length x width x height)/6. For metastasis formation, HT1080 (1×106 cells/injection) or MiaPaCa-2 (5×105 cells/injection) cells expressing different OPN constructs were injected into the tail vein of SCID mice. After 6 weeks, lung tissue was inflated, fixed, embedded, sectioned, and stained with hematoxylin and eosin (H&E). Tumor colonies per lung section were quantified by microscopy.

Histologic Studies

The In Situ Cell Death Detection Kit (Roche, Pleasanton, CA) was used for apoptosis evaluation on paraffin embedded HT1080 and frozen MiaPaCa-2 tumor sections according to the manufacturer's protocol. Sections were also stained with anti CD31 (Santa Cruz Biotechnology, Santa Cruz, CA), Ki67 antibody (Dako North American, Carpinteria, CA), and CD11b antibody (BD PharMingen, San Diego, CA). The human HNSCC tissue microarray was generated and stained for OPN and IKK-β as previously described [31].

In Vitro Apoptosis Evaluation

MiaPaCa-2 and HT1080 cells overexpressing different OPN constructs were plated in 6 cm tissue culture dishes and allowed to adhere for 24 hrs. The cells were washed, permeabilized with 0.1% Triton X-100 and fixed in a 4% paraformaldehyde solution containing 10 ug/mL DAPI (Sigma-Aldrich). Apoptotic nuclei with condensed chromatin or nuclear fragmentation were assessed qualitatively using fluorescent microscopy. TUNEL(+) cells were detected using the In Situ Cell Death Detection Kit (Roche) and quantified by flow cytometry. For the in vitro caspase 3/7 assay, lysates were combined with a lumogenic substrate containing the DEVD sequence. Caspase activity was determined by luciferase luminescence per manufacturer instructions (Promega, Madison, WI).

Inhibition of NF-κB

The p65 siRNA (Dharmacon, Lafayette, CO) was used to inhibit p65 per the manufacturer's protocol.

Inhibition of FAK

PF573228 (Tocris Bioscience, Ellisville, MO) was added to cell culture media at a final concentration of 500 nM. Following a 30 minute pre-incubation, media was removed and replaced with serum-free media containing the inhibitor or vehicle. Cells were incubated in the anoxia incubator, extracts were collected, and immunoblotting was performed. Cells were also analyzed for TUNEL staining by flow cytometry.


Statistical analysis was performed using Statview (SAS Institute Inc, Carey, NY) software. The student T-test and the ANOVA (analysis of variance) test were use to determine the equality of the mean between different groups. Results were considered statistically significant if the p-value was <0.05.


Expression of Different OPN Splice Variants in Human Solid Cancers

We used splice form specific primers and qRT-PCR to determine the presence of OPN-A and B in five tumor cell lines, 24 non-small cell lung cancers (NSCLC) and 30 HNSCC (Fig. S1). Supplementary Figure S1 shows representative RT-PCR for the various human solid cancer cell lines and the 4 STS. Most tumors and cell lines expressed predominantly OPN-A and B but not C. Based on these data we proceeded to assess OPN-A and B levels but not C in human NSCLC and HNSCC. Both NSCLC and HNSCC specimens (Fig. S1) expressed higher levels of OPN-A and B than normal tissues. OPN-A and B levels tracked well with total OPN gene expression on gene array analysis (data not shown). Based on these data, we focused subsequent tumor studies on OPN-A and B splice forms.

The RGD Region Is Critical for Promoting Tumor Growth and Metastasis

Two cell lines, which have either undetectable (MiaPaCa-2) or low basal OPN expression (HT1080), were transfected with mammalian expression plasmids containing OPN-A, OPN-B, OPN-A with mutated RGD sequence (OPN-A-RAA) or OPN-B with deleted RGD sequence (OPN-B-NoRGD). A pool of cells stably overexpressing the desired OPN construct was selected. Figure 1A shows overexpression of different OPN constructs in transfected cells. Note that all OPN isoforms are secreted at similar levels.

Figure 1
OPN promotes tumor growth and metastasis through the RGD domain.

Both MiaPaCa-2 and HT1080 cells were injected subcutaneously into SCID mice and tumor growth was monitored. Tumors transfected with WT OPN-A or B grew significantly faster than the vector control, where as those expressing OPN-A-RAA or OPN-B-NoRGD grew at a similar rate as the vector control cells (Fig. 1B). These differences in tumor growth were not due to changes in cell proliferation because the in vitro proliferation rates of all cell lines were similar (Fig. 1B, bottom panels).

To test the role the RGD domain in both OPN isoforms during metastatic spread, the above cells were injected into the tail veins of SCID mice. After 6 weeks, the lungs were collected and quantified for metastatic lung colonies. Control cells formed few colonies (4–5 colonies/field). However, OPN-A and OPN-B transfected cells formed more numerous and larger metastatic colonies (16 and 13 colonies/field for HT1080 & 28 colonies/field for MiaPaCa-2, respectively; Fig. 1C, p<0.001). In contrast, OPN-A-RAA and OPN-B-NoRGD expressing cells had significantly fewer colonies than the WT isoforms. These studies indicate that OPN promotes metastatic lung colony formation and loss of the RGD sequence suppresses this phenomenon. Both tumor cell types used in these assays express αvβ3 and β1 integrins and can bind to the RGD sequence (data not shown).

OPN Decreases Apoptosis in Tumors in an RGD Dependent Manner

Tissue sections from xenografts expressing different OPN constructs were stained for Ki67 to assess proliferation, CD31 for angiogenesis, CD11b for bone marrow-derived cell infiltration and TUNEL for apoptosis. Ki67, CD31, and CD11b staining were similar between all tumors (data not shown); however, there was a difference in TUNEL staining among the tumor groups. While there were numerous TUNEL(+) regions within the control and OPN-A-RAA tumor sections, these regions were absent in WT OPN-A expressing tumors (Fig. 2A–B). Quantitation of TUNEL(+) cells per high power field (HPF) confirmed these observations (Fig. 2C). Similar results were seen for the OPN-B isoforms, with fewer TUNEL(+) cells in WT OPN-B as compared to OPN-B-NoRGD tumors (Fig. 2D). These results indicate that both OPN isoforms inhibit apoptosis and that this inhibition is mediated through the RGD.

Figure 2
TUNEL staining in MiaPaCa-2 and HT1080 tumor tissues.

Tumor-Derived Secreted OPN Can Suppress Apoptosis but Has No Effect on Cell Adhesion and Migration

Most solid tumors possess regions of reduced oxygen and nutrients. MiaPaCa-2 cells overexpressing different OPN constructs were treated with hypoxia in serum-free media for 48 hrs, which caused cell apoptosis in all groups. However, there were fewer apoptotic nuclei (Fig. 3A) and significantly less TUNEL(+) cells in WT OPN-A expressing cells as compared to vector control (Fig. 3B–C). Mutation of the RGD sequence to RAA prevented OPN-mediated protection of apoptosis from hypoxia and serum starvation (Fig. 3A–C). Similarly, OPN-B overexpression significantly reduced apoptosis under hypoxia and serum starvation in HT1080 cells, and deletion of the RGD sequence reversed this effect (Fig. S2). The conditioned media from WT OPN-A secreting cells, but not OPN-RAA cells, was able to reduce cell death from hypoxia and serum starvation when applied to vector control cells, assessed by Caspase 3/7 activity assay (Fig. 3D). These data indicate that OPN-A and B isoforms inhibit apoptosis induced by hypoxia and serum starvation through the RGD domain.

Figure 3
OPN prevention of apoptosis requires the RGD domain.

To determine the effect of RGD domain on other cellular attributes that may enhance tumor growth or metastasis, we evaluated the effect of OPN overexpression, either WT or with the RGD mutated on cell-cell adhesion (serum free media) and anchorage independent growth (soft agar assay). Neither OPN overexpression or RGD mutation significantly influenced cell-cell adhesion or soft agar growth (assessed for both colony number and size) (Fig. 4A–B). Similarly, neither overexpression of OPN-A or B nor treatment of recombinant OPN isoforms increased cell migration or invasion in the tested cell lines in serum free media (data not shown). Scratch assays also showed that mutation of the RGD did not affect cell migration in serum free media (Fig. 4C). These studies confirm that the main function of the RGD domain is to protect cell from apoptosis.

Figure 4
Overexpression of different OPN isoforms or their mutants does not affect cell-cell adhesion, soft agar colony formation or migration in serum free media.

The RGD Domain of OPN Mediates Apoptosis Partially via NF-κB Activation

NF-κB activation protects cells from apoptosis and OPN can promote NF-κB activation. Hence, we evaluated NF-κB activity in MiaPaCa-2 cells expressing different OPN constructs. Overexpression of WT OPN isoforms resulted in significant increase of NF-κB-dependent luciferase activity and either mutation (OPN-A-RAA) or deletion (OPN-B-NoRGD) of the RGD domain eliminated this effect, although the absolute effect was modest (Fig. 5A). We also assessed protein expression of selective NF-κB endogenous targets. OPN-A or OPN-B overexpressing cells had higher Bcl-2 and XIAP protein levels than vector control, OPN-A-RAA and OPN-B-NoRGD cells (Fig. 5B). These results indicate that OPN activates NF-κB under stressed conditions, and the RGD domain of OPN mediates this effect.

Figure 5
The RGD domain of OPN enhances NF-κB activation under stress conditions and partially protects cells from apoptosis.

MiaPaCa-2 cells overexpressing different OPN constructs were transiently transfected with a p65 siRNA oligo to inhibit NF-κB activation. Transfection with this oligo had minimal effect on apoptosis in control, OPN-A-RAA or OPN-B-NoRGD cells under stressed conditions (Fig. 5C). In contrast, inhibition of p65 increased the number of TUNEL(+) cells in those overexpressing either WT OPN-A or B compared to the scrambled control (13.8% vs. 7.5% and 13.6% vs. 6.6%, respectively, Fig. 5C). However, the level of apoptosis with NF-κB inhibition in WT OPN cells was still less than that observed in vector control or OPN-A-RAA cells, suggesting that NF-κB activation alone may only be partially responsible for OPN-mediated cell survival.

IκB Kinase β (IKK-β) activates NF-κB through phosphorylation and degradation of IκB-α. High IKK-β correlates with increased NF-κB activity and vice-versa. Although we cannot directly measure NF-κB activity in archival human cancer tissues, we can stain them for IKK-β as a surrogate marker for NF-κB activity. We stained a tissue microarray containing 89 HNSCCs for OPN and IKK-β. We found a significant correlation between OPN and IKK-β expression (p = 0.025, Fisher exact test). Concordant expression between the two markers was noted in 70 tumors and discordant expression in 19 tumors (data not shown). These results suggest that NF-κB activity and OPN expression are strongly related in human tumors.

The RGD Segment of OPN Also Mediates Apoptosis Partially via FAK Activation

Since the RGD sequence binds to αv integrins, which are known to signal through the FAK pathway, and OPN activates FAK in cell migration, we also evaluated the effect of RGD mutation on the activation of this pathway. MiaPaCa-2 cells expressing different OPN constructs were subjected to hypoxia and serum starvation. Prior to hypoxia and serum starvation, pFAK levels were elevated in all cells. After 30–60 min of hypoxia and serum starvation, FAK phosphorylation decreased in the vector control and OPN-A-RAA cells, whereas they remained high in WT OPN-A expressing cells (Fig. 6A). These results indicate that the RGD domain within OPN is important for sustaining FAK activation under stress.

Figure 6
The RGD domain of OPN activates FAK and partially protects cells from apoptosis under stress conditions.

To suppress FAK activation, MiaPaCa-2 cells expressing OPN isoforms were pre-treated with the FAK-specific inhibitor PF573228 (500 nM) or the vehicle for 30 min followed by exposure to hypoxia. As shown in Figure 6B, pretreatment with the FAK inhibitor completely blocked FAK phosphorylation at the tyrosine 397 residue in all cells.

As previously shown, overexpression of OPN-A or B did not enhance cell migration or invasion in evaluated cell lines. To determine if FAK phosphorylation is required for OPN-mediated cell survival under hypoxia and serum-starvation, MiaPaCa-2 cells expressing different OPN constructs were treated with PF573228 under these conditions. Addition of FAK inhibitor led to a small increase in TUNEL(+) cells under control conditions, suggesting a modest cytotoxic effect of the drug alone (Fig. 6C, N+Vehicle vs N+Inhibitor). However, under serum starved/hypoxia treatment, the addition of PF573228 strongly increased the percentage of TUNEL(+) cells for OPN-A expressing cells compared to vehicle (Fig. 6C). In contrast, the percentage of TUNEL(+) cells was only slightly elevated in control and OPN-A-RAA cells treated with PF573228. Taken together, these data suggest that OPN activates FAK through an RGD-dependent mechanism, which protects cells from apoptosis during hypoxia and serum starvation.

Since AKT has been shown to be activated by OPN and is a well-known survival factor, we also assessed AKT phosphorylation for cells transfected with different constructs under different conditions. There was no difference in the level of either total or phospho-AKT for cells expressing different constructs under hypoxia and serum starvation (Fig. S3).


The effect of modulating OPN expression has been studied in many cancer types. Overexpression of OPN increased growth [32], [33], whereas inhibition of OPN reduced growth in multiple tumor types [32], [34], [35]. These gain and loss of function studies indicate that OPN is involved in modulating tumor growth; however, the importance of the RGD domain within OPN in different OPN isoforms has not been rigorously characterized genetically. Here, we systematically define the effect of the RGD domain on tumor progression by either mutation or deletion in 2 different OPN isoforms and express them in different cell types. Overexpression of OPN isoforms containing the WT RGD, but not those with the RGD region mutated or removed, enhanced both local tumor growth and metastatic lung colony formation. In fact, the RGD domain was essential for tumor growth promotion in our xenograft models.

Interestingly, our mouse tumor data indicate that the RGD domain of OPN mediates tumor growth and metastasis mainly through decreased apoptosis. Similar findings were noted for in vitro assays. Overexpression of WT OPN but not mutant RGD protects cells from apoptosis triggered by hypoxia and serum starvation. However, such overexpression did not affect cell adhesion, migration or anchorage independent growth.

Although our results, which show that the major function of the RGD domain is to protect cancer cells from stress-induced apoptosis are different from prior studies using recombinant bacterially derived OPN [36], [37], [38], [39], they are consistent with studies which used human-derived soluble OPN or antibodies that block autocrine OPN function [40], [41], [42], [43]. OPN deficient mice have higher TUNEL staining and less papilloma development when treated with carcinogen compared to WT mice [44]. Reducing OPN expression by RNA interference leads to increased TUNEL staining and caspase-3 activity [45]. Mechanistically, OPN has been shown to counteract the pro-apoptotic effect of serum starvation in two-dimensional [40] and three-dimensional cultures [41], through the RGD domain. Interestingly, intracellular cleavage of OPN by caspase 3 and 8 can enhance apoptotic cell death under hypoxia and reoxygenation, and one of the cleavage sites is located immediately adjacent to the RGD [43]. Collectively, these reports suggest that OPN isoforms promote both tumor growth and metastasis through the same mechanism, which is to protect cells from apoptosis under the stresses encountered within the tumor microenvironment, notably through the RGD domain. Since the RGD domain of OPN interacts with multiple cellular receptors including the αv family of integrins, strategies that block such an interaction may be beneficial in the treatment of solid tumors. For example, CNTO 95, a fully human anti-αv integrin monoclonal antibody, has been shown to have antitumor activity by itself [46], [47] and can enhance the therapeutic efficacy of fractionated radiation therapy in xenografts via increasing apoptosis [48]. Several clinical studies are ongoing to test the toxicity and efficacy of such anti-integrin antibody either alone or in combination with conventional therapy in solid tumors.

OPN is well known in the literature as a survival factor that mediates cell apoptosis under certain pathological stresses. It has been shown to inhibit cell apoptosis in several systems including cardiac myocytes from ischemia/reperfusion injury [49], endothelial cells from growth factor deprivation [40], intestinal epithelial cells from inflammation [50] and immune cells from certain stresses [51], [52], [53]. However, the detailed pathways and mechanisms by which OPN mediates its anti-apoptotic effect can be different for various cell types and stressors. NF-κB activation is believed to be a major effector of OPN-mediated cell survival. OPN protects cells from denatured collagen II, by increasing p50 and p65 DNA binding [54]. Soluble OPN protects lymphocytes from apoptosis, by activating NF-κB [55]. Inhibition of OPN leads to increased cell death, increased TUNEL staining, decreased NF-κB binding and increased levels of the inhibitor IκB-α [34]. Furthermore, interaction between the RGD domain of OPN and integrin αvβ3 receptors leads to NF-κB activation and cell survival [56]. Our data confirm that overexpression of OPN isoforms containing the RGD domain lead to enhanced NF-κB activation, while isoforms lacking the RGD domain do not. Such activation does occur in actual human HNSCC as suggested by co-localization between OPN and IKK-β, a target of NF-kB pathway [57], [58]. Inhibition of NF-κB activity partially suppresses OPN-mediated protection from apoptosis in hypoxic/serum-starved cells. Our data therefore indicates that NF-κB activation is at least partially responsible for OPN mediated survival via the RGD domain.

FAK activation promotes cell proliferation, survival and migration [59]. FAK is tyrosine phosphorylated in response to ligation of β1 or β3 integrins [60]. Since the RGD domain of OPN binds to αvβ3 and αvβ1 integrins, FAK activation was measured in cell lines overexpressing OPN isoforms. WT OPN isoforms, but not those lacking the RGD domain, retained FAK phosphorylation in hypoxic/serum-starved cells. These results are similar to those previously published [61], [62]. Moreoever, inhibition of FAK phosphorylation with a specific inhibitor resulted in a marked enhancement of apoptosis seen only in WT OPN expressing cells but not those with mutated OPN-A isoform. Our data indicates that FAK is another survival pathway that is regulated by the RGD domain of OPN. However, not all survival pathways are engaged by the RGD domain of OPN as AKT is one such pathway (Figure S3) [63], indicating that RGD activation of survival pathways under hypoxia and serum starvation is a specific process.

Little is known about the function of different OPN isoforms in human tumors. The first study which systematically evaluated the expression and function of different OPN splice forms in breast cancer indicated that OPN-C was selectively expressed in invasive breast cancer and more likely to support anchorage independent tumor growth than OPN-A in a breast cancer cell line. However, subsequent studies have found that OPN-A and B are more likely to be expressed in hepatocellular carcinoma and lung cancer than OPN-C [64], [65]. Overexpression of OPN-A and to some extent OPN-B in NSCLC cell lines resulted in increased VEGF secretion and bovine capillary tube length formation, whereas the reverse was noted for OPN-C overexpression [64]. Similarly, OPN-A and B induced Hep3B cell migration, while OPN-C had no significant effects [65]. These data are consistent with our findings, indicating that OPN-A and B are the predominant isoforms found in solid tumors and that both can enhance tumor growth and metastasis at an equivalent level.

In summary, expression of both OPN-A and OPN-B isoforms are commonly observed in NSCLC and HNSCC. Forced overexpression of either isoform promotes tumor growth and metastasis, and the RGD domain within OPN is required for the effect to occur. OPN overexpressing cells have reduced apoptotic cell death both in vivo and in vitro. OPN, acting through the RGD domain, protects the cells by activating NF-κB and FAK but not AKT. These data indicate that the predominant mechanism, by which OPN promotes tumor growth and metastasis through the RGD domain, is enhancement of survival in the tumor microenvironment. Therefore inhibitors directed against OPN should target multiple isoforms and should inhibit cell survival mechanisms that involve the RGD domain, FAK phosphorylation and NF-κB activation.

Supporting Information

Figure S1

Expression of OPN-A and OPN-B isoforms in human cancer cell lines and primary human tumors. Poly-A RNA was extracted from human STS including giant cell tumor (GCT), pigmented villonodular synovial tumor (PVNS) and leiomyosarcoma (LMS) samples and amplified by RT-PCR using the universal OPN primer set (left) (A). HT1080 RNA was used as a positive control for OPN-A and OPN-B expression (A, right lane). RNAs extracted from the indicated human cancer cell lines were subjected to RT-PCR and resulting cDNAs were amplified using the universal OPN primer set (right panel) (A). pCDNA -OPN-A and B plasmids were used as positive controls for the amplification of the indicated OPN isoforms. NS indicates non-specific band (A, right panel). The fold increase of NSCLC OPN-A (stripe) and OPN-B (black) mRNA expression relative to 18S in human NSCLC specimens (LCC) and Normal Lung Tissue (NOR)( B) or in human HNSCC normalized to HN99 (one HNSCC sample) (C), based on qRT-PCR assay is shown. Tumors were arranged by overall total OPN mRNA expression based on gene expression data with increasing expression from left to right (B and C).

(0.42 MB TIF)

Figure S2

Percentage of TUNEL(+) cells in HT1080 cells transfected with different OPN constructs under hypoxia in serum free media.

(0.10 MB TIF)

Figure S3

Immunoblot showing total AKT and pAKT expression for MiaPaCa-2 cells expressing different OPN constructs under normoxia or 1 hour of hypoxia in serum free media. β-actin bands confirmed equal loading.

(0.17 MB TIF)


Competing Interests: The authors have declared that no competing interests exist.

Funding: This investigation was supported by Public Health Service Grant Number CA09302 (DC) and P01- CA67166 (QTL, AB, HC, DC, PK, NCD, AK, AJG) awarded by the National Cancer Institute, Department of Health and Human Services. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.


1. Denhardt DT, Noda M. Osteopontin expression and function: role in bone remodeling. J Cell Biochem. 1998;Suppl 30–31:92–102. [PubMed]
2. Ashkar S, Weber GF, Panoutsakopoulou V, Sanchirico ME, Jansson M, et al. Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science. 2000;287:860–864. [PubMed]
3. Gravallese EM. Osteopontin: a bridge between bone and the immune system. J Clin Invest. 2003;112:147–149. [PMC free article] [PubMed]
4. Tuck AB, Chambers AF, Allan AL. Osteopontin overexpression in breast cancer: knowledge gained and possible implications for clinical management. J Cell Biochem. 2007;102:859–868. [PubMed]
5. Wai PY, Kuo PC. The role of Osteopontin in tumor metastasis. J Surg Res. 2004;121:228–241. [PubMed]
6. Rittling SR, Chambers AF. Role of osteopontin in tumour progression. Br J Cancer. 2004;90:1877–1881. [PMC free article] [PubMed]
7. Wai PY, Kuo PC. Osteopontin: regulation in tumor metastasis. Cancer Metastasis Rev. 2008;27:103–118. [PubMed]
8. Oldberg A, Franzen A, Heinegard D. Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence. Proc Natl Acad Sci U S A. 1986;83:8819–8823. [PMC free article] [PubMed]
9. Yokosaki Y, Tanaka K, Higashikawa F, Yamashita K, Eboshida A. Distinct structural requirements for binding of the integrins alphavbeta6, alphavbeta3, alphavbeta5, alpha5beta1 and alpha9beta1 to osteopontin. Matrix Biol. 2005;24:418–427. [PubMed]
10. Miyauchi A, Alvarez J, Greenfield EM, Teti A, Grano M, et al. Recognition of osteopontin and related peptides by an alpha v beta 3 integrin stimulates immediate cell signals in osteoclasts. J Biol Chem. 1991;266:20369–20374. [PubMed]
11. Hu DD, Hoyer JR, Smith JW. Characterization of the interaction between integrins and recombinant human osteopontin. Ann N Y Acad Sci. 1995;760:312–314. [PubMed]
12. Hu DD, Lin EC, Kovach NL, Hoyer JR, Smith JW. A biochemical characterization of the binding of osteopontin to integrins alpha v beta 1 and alpha v beta 5. J Biol Chem. 1995;270:26232–26238. [PubMed]
13. Liaw L, Skinner MP, Raines EW, Ross R, Cheresh DA, et al. The adhesive and migratory effects of osteopontin are mediated via distinct cell surface integrins. Role of alpha v beta 3 in smooth muscle cell migration to osteopontin in vitro. J Clin Invest. 1995;95:713–724. [PMC free article] [PubMed]
14. Senger DR, Perruzzi CA, Papadopoulos-Sergiou A, Van de Water L. Adhesive properties of osteopontin: regulation by a naturally occurring thrombin-cleavage in close proximity to the GRGDS cell-binding domain. Mol Biol Cell. 1994;5:565–574. [PMC free article] [PubMed]
15. Liaw L, Almeida M, Hart CE, Schwartz SM, Giachelli CM. Osteopontin promotes vascular cell adhesion and spreading and is chemotactic for smooth muscle cells in vitro. Circ Res. 1994;74:214–224. [PubMed]
16. Yue TL, McKenna PJ, Ohlstein EH, Farach-Carson MC, Butler WT, et al. Osteopontin-stimulated vascular smooth muscle cell migration is mediated by beta 3 integrin. Exp Cell Res. 1994;214:459–464. [PubMed]
17. Philip S, Bulbule A, Kundu GC. Osteopontin stimulates tumor growth and activation of promatrix metalloproteinase-2 through nuclear factor-kappa B-mediated induction of membrane type 1 matrix metalloproteinase in murine melanoma cells. J Biol Chem. 2001;276:44926–44935. [PubMed]
18. Christensen B, Nielsen MS, Haselmann KF, Petersen TE, Sorensen ES. Post-translationally modified residues of native human osteopontin are located in clusters: identification of 36 phosphorylation and five O-glycosylation sites and their biological implications. Biochem J. 2005;390:285–292. [PMC free article] [PubMed]
19. Christensen B, Kazanecki CC, Petersen TE, Rittling SR, Denhardt DT, et al. Cell type-specific post-translational modifications of mouse osteopontin are associated with different adhesive properties. J Biol Chem. 2007;282:19463–19472. [PubMed]
20. Kazanecki CC, Uzwiak DJ, Denhardt DT. Control of osteopontin signaling and function by post-translational phosphorylation and protein folding. J Cell Biochem. 2007;102:912–924. [PubMed]
21. Rittling SR, Chen Y, Feng F, Wu Y. Tumor-derived osteopontin is soluble, not matrix associated. J Biol Chem. 2002;277:9175–9182. [PubMed]
22. Allan AL, George R, Vantyghem SA, Lee MW, Hodgson NC, et al. Role of the integrin-binding protein osteopontin in lymphatic metastasis of breast cancer. Am J Pathol. 2006;169:233–246. [PMC free article] [PubMed]
23. He B, Mirza M, Weber GF. An osteopontin splice variant induces anchorage independence in human breast cancer cells. Oncogene. 2006;25:2192–2202. [PubMed]
24. Mirza M, Shaughnessy E, Hurley JK, Vanpatten KA, Pestano GA, et al. Osteopontin-c is a selective marker of breast cancer. Int J Cancer. 2008;122:889–897. [PubMed]
25. Ivanov SV, Ivanova AV, Goparaju CM, Chen Y, Beck A, et al. Tumorigenic properties of alternative osteopontin isoforms in mesothelioma. Biochem Biophys Res Commun. 2009;382:514–518. [PubMed]
26. Zhu Y, Denhardt DT, Cao H, Sutphin PD, Koong AC, et al. Hypoxia upregulates osteopontin expression in NIH-3T3 cells via a Ras-activated enhancer. Oncogene 2005 [PubMed]
27. Loster K, Schuler C, Heidrich C, Horstkorte R, Reutter W. Quantification of cell-matrix and cell-cell adhesion using horseradish peroxidase. Anal Biochem. 1997;244:96–102. [PubMed]
28. Graves EE, Quon A, Loo BW., Jr RT_Image: an open-source tool for investigating PET in radiation oncology. Technol Cancer Res Treat. 2007;6:111–121. [PubMed]
29. Erler JT, Bennewith KL, Nicolau M, Dornhofer N, Kong C, et al. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature. 2006;440:1222–1226. [PubMed]
30. Le QT, Sutphin PD, Raychaudhuri S, Yu SC, Terris DJ, et al. Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas. Clin Cancer Res. 2003;9:59–67. [PubMed]
31. Le QT, Kong C, Lavori PW, O'Byrne K, Erler JT, et al. Expression and Prognostic Significance of a Panel of Tissue Hypoxia Markers in Head-and-Neck Squamous Cell Carcinomas. Int J Radiat Oncol Biol Phys. 2007;69:167–175. [PubMed]
32. Chakraborty G, Jain S, Kundu GC. Osteopontin promotes vascular endothelial growth factor-dependent breast tumor growth and angiogenesis via autocrine and paracrine mechanisms. Cancer Res. 2008;68:152–161. [PubMed]
33. Cui R, Takahashi F, Ohashi R, Gu T, Yoshioka M, et al. Abrogation of the interaction between osteopontin and alphavbeta3 integrin reduces tumor growth of human lung cancer cells in mice. Lung Cancer. 2007;57:302–310. [PubMed]
34. Zhao J, Dong L, Lu B, Wu G, Xu D, et al. Down-regulation of osteopontin suppresses growth and metastasis of hepatocellular carcinoma via induction of apoptosis. Gastroenterology. 2008;135:956–968. [PubMed]
35. Gong M, Lu Z, Fang G, Bi J, Xue X. A small interfering RNA targeting osteopontin as gastric cancer therapeutics. Cancer Lett 2008 [PubMed]
36. Furger KA, Allan AL, Wilson SM, Hota C, Vantyghem SA, et al. Beta(3) integrin expression increases breast carcinoma cell responsiveness to the malignancy-enhancing effects of osteopontin. Mol Cancer Res. 2003;1:810–819. [PubMed]
37. Nasu K, Ishida T, Setoguchi M, Higuchi Y, Akizuki S, et al. Expression of wild-type and mutated rabbit osteopontin in Escherichia coli, and their effects on adhesion and migration of P388D1 cells. Biochem J. 1995;307(Pt 1):257–265. [PMC free article] [PubMed]
38. Tuck AB, Elliott BE, Hota C, Tremblay E, Chambers AF. Osteopontin-induced, integrin-dependent migration of human mammary epithelial cells involves activation of the hepatocyte growth factor receptor (Met). J Cell Biochem. 2000;78:465–475. [PubMed]
39. Mi Z, Guo H, Wai PY, Gao C, Kuo PC. Integrin-linked kinase regulates osteopontin-dependent MMP-2 and uPA expression to convey metastatic function in murine mammary epithelial cancer cells. Carcinogenesis. 2006;27:1134–1145. [PubMed]
40. Khan SA, Lopez-Chua CA, Zhang J, Fisher LW, Sorensen ES, et al. Soluble osteopontin inhibits apoptosis of adherent endothelial cells deprived of growth factors. J Cell Biochem. 2002;85:728–736. [PubMed]
41. Geissinger E, Weisser C, Fischer P, Schartl M, Wellbrock C. Autocrine stimulation by osteopontin contributes to antiapoptotic signalling of melanocytes in dermal collagen. Cancer Res. 2002;62:4820–4828. [PubMed]
42. Gu T, Ohashi R, Cui R, Tajima K, Yoshioka M, et al. Osteopontin is involved in the development of acquired chemo-resistance of cisplatin in small cell lung cancer. Lung Cancer. 2009;66:176–183. [PubMed]
43. Kim HJ, Lee HJ, Jun JI, Oh Y, Choi SG, et al. Intracellular cleavage of osteopontin by caspase-8 modulates hypoxia/reoxygenation cell death through p53. Proc Natl Acad Sci U S A. 2009;106:15326–15331. [PMC free article] [PubMed]
44. Hsieh YH, Juliana MM, Hicks PH, Feng G, Elmets C, et al. Papilloma development is delayed in osteopontin-null mice: implicating an antiapoptosis role for osteopontin. Cancer Res. 2006;66:7119–7127. [PubMed]
45. Nystrom T, Duner P, Hultgardh-Nilsson A. A constitutive endogenous osteopontin production is important for macrophage function and differentiation. Exp Cell Res. 2007;313:1149–1160. [PubMed]
46. Trikha M, Zhou Z, Nemeth JA, Chen Q, Sharp C, et al. CNTO 95, a fully human monoclonal antibody that inhibits alphav integrins, has antitumor and antiangiogenic activity in vivo. Int J Cancer. 2004;110:326–335. [PubMed]
47. Martin PL, Jiao Q, Cornacoff J, Hall W, Saville B, et al. Absence of adverse effects in cynomolgus macaques treated with CNTO 95, a fully human anti-alphav integrin monoclonal antibody, despite widespread tissue binding. Clin Cancer Res. 2005;11:6959–6965. [PubMed]
48. Ning S, Nemeth JA, Hanson RL, Forsythe K, Knox SJ. Anti-integrin monoclonal antibody CNTO 95 enhances the therapeutic efficacy of fractionated radiation therapy in vivo. Mol Cancer Ther. 2008;7:1569–1578. [PubMed]
49. Zohar R, Zhu B, Liu P, Sodek J, McCulloch CA. Increased cell death in osteopontin-deficient cardiac fibroblasts occurs by a caspase-3-independent pathway. Am J Physiol Heart Circ Physiol. 2004;287:H1730–1739. [PubMed]
50. Da Silva AP, Pollett A, Rittling SR, Denhardt DT, Sodek J, et al. Exacerbated tissue destruction in DSS-induced acute colitis of OPN-null mice is associated with downregulation of TNF-alpha expression and non-programmed cell death. J Cell Physiol. 2006;208:629–639. [PubMed]
51. Denhardt DT, Noda M, O'Regan AW, Pavlin D, Berman JS. Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest. 2001;107:1055–1061. [PMC free article] [PubMed]
52. Burdo TH, Wood MR, Fox HS. Osteopontin prevents monocyte recirculation and apoptosis. J Leukoc Biol. 2007;81:1504–1511. [PMC free article] [PubMed]
53. Hur EM, Youssef S, Haws ME, Zhang SY, Sobel RA, et al. Osteopontin-induced relapse and progression of autoimmune brain disease through enhanced survival of activated T cells. Nat Immunol. 2007;8:74–83. [PubMed]
54. Fan K, Dai J, Wang H, Wei H, Cao Z, et al. Treatment of collagen-induced arthritis with an anti-osteopontin monoclonal antibody through promotion of apoptosis of both murine and human activated T cells. Arthritis Rheum. 2008;58:2041–2052. [PubMed]
55. Cao Z, Dai J, Fan K, Wang H, Ji G, et al. A novel functional motif of osteopontin for human lymphocyte migration and survival. Mol Immunol. 2008;45:3683–3692. [PubMed]
56. Scatena M, Almeida M, Chaisson ML, Fausto N, Nicosia RF, et al. NF-kappaB mediates alphavbeta3 integrin-induced endothelial cell survival. J Cell Biol. 1998;141:1083–1093. [PMC free article] [PubMed]
57. Philip S, Kundu GC. Osteopontin induces nuclear factor kappa B-mediated promatrix metalloproteinase-2 activation through I kappa B alpha/IKK signaling pathways, and curcumin (diferulolylmethane) down-regulates these pathways. J Biol Chem. 2003;278:14487–14497. [PubMed]
58. Rice J, Courter DL, Giachelli CM, Scatena M. Molecular mediators of alphavbeta3-induced endothelial cell survival. J Vasc Res. 2006;43:422–436. [PubMed]
59. Hood JD, Cheresh DA. Role of integrins in cell invasion and migration. Nat Rev Cancer. 2002;2:91–100. [PubMed]
60. Hehlgans S, Haase M, Cordes N. Signalling via integrins: implications for cell survival and anticancer strategies. Biochim Biophys Acta. 2007;1775:163–180. [PubMed]
61. Fong YC, Liu SC, Huang CY, Li TM, Hsu SF, et al. Osteopontin increases lung cancer cells migration via activation of the alphavbeta3 integrin/FAK/Akt and NF-kappaB-dependent pathway. Lung Cancer 2008 [PubMed]
62. Li JJ, Han M, Wen JK, Li AY. Osteopontin stimulates vascular smooth muscle cell migration by inducing FAK phosphorylation and ILK dephosphorylation. Biochem Biophys Res Commun. 2007;356:13–19. [PubMed]
63. Lin YH, Yang-Yen HF. The osteopontin-CD44 survival signal involves activation of the phosphatidylinositol 3-kinase/Akt signaling pathway. J Biol Chem. 2001;276:46024–46030. [PubMed]
64. Blasberg JD, Goparaju CM, Pass HI, Donington JS. Lung cancer osteopontin isoforms exhibit angiogenic functional heterogeneity. J Thorac Cardiovasc Surg 2009 [PMC free article] [PubMed]
65. Chae S, Jun HO, Lee EG, Yang SJ, Lee DC, et al. Osteopontin splice variants differentially modulate the migratory activity of hepatocellular carcinoma cell lines. Int J Oncol. 2009;35:1409–1416. [PubMed]

Articles from PLoS ONE are provided here courtesy of Public Library of Science
PubReader format: click here to try


Save items

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...


  • Compound
    PubChem chemical compound records that cite the current articles. These references are taken from those provided on submitted PubChem chemical substance records. Multiple substance records may contribute to the PubChem compound record.
  • Gene
    Gene records that cite the current articles. Citations in Gene are added manually by NCBI or imported from outside public resources.
  • GEO Profiles
    GEO Profiles
    Gene Expression Omnibus (GEO) Profiles of molecular abundance data. The current articles are references on the Gene record associated with the GEO profile.
  • HomoloGene
    HomoloGene clusters of homologous genes and sequences that cite the current articles. These are references on the Gene and sequence records in the HomoloGene entry.
  • MedGen
    Related information in MedGen
  • PubMed
    PubMed citations for these articles
  • Substance
    PubChem chemical substance records that cite the current articles. These references are taken from those provided on submitted PubChem chemical substance records.

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...